protein

Recombinant Human Chromatin Modifying Protein 2A

MBS143056

0.005 mg

140 USD

Recombinant Protein

Recombinant Human Chromatin Modifying Protein 2A

Chromatin Modifying Protein 2A

CHMP2A Human; Chromatin Modifying Protein 2A Human Recombinant; Charged multivesicular body protein 2a; Chromatin-modifying protein 2a; Vacuolar protein-sorting-associated protein 2-1; Putative breast adenocarcinoma marker BC-2; Vps2-1; hVps2-1; CHMP2A; BC2; CHMP2; BC-2; VPS2; VPS2A

charged multivesicular body protein 2a; Charged multivesicular body protein 2a; charged multivesicular body protein 2a; VPS2 homolog A; chromatin modifying protein 2A; putative breast adenocarcinoma marker (32kD); putative breast adenocarcinoma marker BC-2; vacuolar protein sorting-associated protein 2-1; vps2-1; charged multivesicular body protein 2A; Chromatin-modifying protein 2a; CHMP2a; Putative breast adenocarcinoma marker BC-2; Vacuolar protein sorting-associated protein 2-1; Vps2-1; hVps2-1

CHMP2A

CHMP2A; CHMP2A; BC2; BC-2; VPS2; CHMP2; VPS2A; BC2; CHMP2; CHMP2a; Vps2-1; hVps2-1

CHM2A_HUMAN

E Coli

222

Greater than 90.0% as determined by SDS-PAGE.

The CHMP2A solution contains 20mM Tris-HCl buffer (pH8.0), 0.1M NaCl 1mM DTT, and 30% glycerol. Sterile Filtered colorless solution.

Store at 4 degree C if entire vial will be used within 2-4 weeks. Store, frozen at -20 degree C for longer periods of time. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).Avoid multiple freeze-thaw cycles.

RECOMBINANT & NATURAL PROTEINS; Recombinant Proteins; Chromatin Modifying Protein

Description: CHMP2A Human Recombinant fused with a 20 amino acid His tag at N-terminus produced in E Coli is a single, non-glycosylated, polypeptide chain containing 242 amino acids (1-222 a.a.) and having a molecular mass of 27.2 kDa.The CHMP2A is purified by proprietary chromatographic techniques. Introduction: Chromatin modifying protein 2A (CHMP2A) is a member of the SNF7 family and it is a component of the ESCRT III complex, which is required for MVBs (multivesicular bodies) formation and sorting of endosomal cargo proteins into MVBs. The MVB pathway mediates release of transmembrane proteins into the lumen of the lysosome for degradation. The MVB pathway requires the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins generally detach from the invaginating membrane before the ILV (intraluminal vesicles) is released. ESCRT-III proteins are thought to mediate the basic vesicle extrusion and/or membrane fission activities, probably in conjunction with the AAA ATPase VPS4.

7656922

NP_055268.1

NM_014453.3

O43633

25,104 Da

Budding And Maturation Of HIV Virion Pathway (106009); Disease Pathway (530764); ESCRT-III Complex Pathway (413475); ESCRT-III Complex Pathway (890627); Endocytosis Pathway (102279); Endocytosis Pathway (102181); Endosomal Sorting Complex Required For Transport (ESCRT) Pathway (205244); HIV Infection Pathway (105983); HIV Life Cycle Pathway (105984); Late Phase Of HIV Life Cycle Pathway (105995)

CHMP2A belongs to the chromatin-modifying protein/charged multivesicular body protein (CHMP) family. These proteins are components of ESCRT-III (endosomal sorting complex required for transport III), a complex involved in degradation of surface receptor proteins and formation of endocytic multivesicular bodies (MVBs). Some CHMPs have both nuclear and cytoplasmic/vesicular distributions, and one such CHMP, CHMP1A (MIM 164010), is required for both MVB formation and regulation of cell cycle progression (Tsang et al., 2006 [PubMed 16730941]).[supplied by OMIM, Mar 2008]

CHMP2A: Probable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV- 1 p6- and p9-dependent virus release. Belongs to the SNF7 family. Chromosomal Location of Human Ortholog: 19q. Cellular Component: membrane coat; membrane; late endosome membrane; cytosol. Molecular Function: protein domain specific binding; protein binding; phosphatidylcholine binding. Biological Process: protein polymerization; cell separation during cytokinesis; viral reproduction; protein heterooligomerization; vacuolar transport; regulation of viral reproduction; viral infectious cycle; endosome transport; mitotic metaphase plate congression; protein transport; establishment of protein localization; membrane invagination; protein homooligomerization; nuclear organization and biogenesis

0.005 mg

140 USD

0.02 mg

205

1 mg

3490